-
Study Says Ocrevus Depletes Certain T-cells in MS Patients
A single dose of Ocrevus (ocrelizumab) depleted immune T-cells within two weeks in patients with relapsing and primary progressive MS, a study shows. Click here to read more about this study and its findings.
What do you think about this study and its findings? Does this news impact your opinion on Ocrevus?
Sorry, there were no replies found.
Log in to reply.